MolNFT v1 · #123940 · protein
Recombinant bovine beta-lactoglobulin with uncleaved N-terminal methionine (rblgb)
5K06: “Recombinant bovine beta-lactoglobulin with uncleaved N-terminal methionine (rblgb)”. X-ray diffraction, 1 ligand (MYR), 2 pockets (best druggability 0.70). MolNFT v1 #123940 on GenesisL1: 3D structure, binding sites and pockets in…
- PDB
- 5K06
- Type
- protein
- Length
- 157 residues
- Chains
- 1
- Method
- x-ray diffraction
- Collection
- MolNFT v1 / PDB
- Contract
- 0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
- Owner
- 0x3396CDB397284571d12822B4ae1189a8E22AAAAA
- Molecule
- Beta-lactoglobulin
- UniProt
- P02754
- Ligands
- MYR
- Pockets
- 2 · best druggability 0.70
Structure
x-ray diffraction · 1 distinct chain · 15% helix, 43% strand (DSSP).
| Chain | Molecule | Type | Residues | Secondary structure | UniProt |
|---|---|---|---|---|---|
| A | Beta-lactoglobulin | protein | 157 | 15% helix, 43% strand | P02754 |
Ligands and binding sites
- MYR · Myristic acid · ligand · chains A
- GOL · Glycerol · additive · chains A
- SIN · Succinic acid · additive · chains A
Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.
Pockets
2 pockets found on a 1 Å grid, 1 with a druggability of 0.5 or more.
| Volume (ų) | Druggability | Buriedness | Lining residues | Inside | |
|---|---|---|---|---|---|
| 1 | 188 | 0.70 | 0.86 | 29 | MYR |
| 2 | 116 | 0.39 | 0.75 | 23 | empty |
Modifications
Observed in the structure: 2 disulfide (disulfide).
Compared structures
- 5K06 · Recombinant bovine beta-lactoglobulin with uncleaved N-terminal methionine (rBlgB) · the same entry in another collection · chain A against A, TM-score 1.00
Analyse
- Open in the research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides and crosslinks on the 3D structure
- Every structure of UniProt P02754
- Elsewhere: RCSB PDB 5K06 · PDBe 5K06 · UniProt P02754
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.